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Abstract 
Background: SPI1 is an essential transcription factor (TF) for the hematopoietic lineage, in which its expression is 
tightly controlled through a −17‑kb upstream regulatory region and a promoter region. Both regulatory regions are 
demethylated during hematopoietic development, although how the change of DNA methylation status is per‑
formed is still unknown.
Results: We found that the ectopic overexpression of RUNX1 (another key TF in hematopoiesis) in HEK‑293T cells 
induces almost complete DNA demethylation at the −17‑kb upstream regulatory region and partial but significant 
DNA demethylation at the proximal promoter region. This DNA demethylation occurred in mitomycin‑C‑treated 
nonproliferating cells at both regulatory regions, suggesting active DNA demethylation. Furthermore, ectopic RUNX1 
expression induced significant endogenous SPI1 expression, although its expression level was much lower than that 
of natively SPI1‑expressing monocyte cells.
Conclusions: These results suggest the novel role of RUNX1 as an inducer of DNA demethylation at the SPI1 regula‑
tory regions, although the mechanism of RUNX1‑induced DNA demethylation remains to be explored.
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Background
SPI1 is a hematopoietic lineage-specific TF belong-
ing to the ETS family [1]. It plays an important role in 
the development of myeloid and lymphoid cells and is 
highly expressed in monocytes [2, 3]. The expression of 
SPI1 is regulated by the combined activity of a proximal 
promoter and an upstream regulatory element (URE) 
located −17-kb upstream of the transcription start site 
(also known as the distal promoter region) in human [3, 
4]. Deletion of the URE region contributes to the exacer-
bation of acute myeloid leukemia (AML) or erythroleu-
kemia [5, 6]. The SPI1 regulatory regions are differentially 
methylated in SPI1-expressing and nonexpressing cell 
lines [7, 8]. This differential pattern is also maintained 
during hematopoietic differentiation, in which ES cells 
are hypermethylated while hematopoietic stem cells 
become hypomethylated [7–9]. Meanwhile, abnormal 
hypermethylation of the SPI1 regulatory regions is fre-
quently observed in myeloma cell lines with downregu-
lated SPI1 [10]. Thus, this methylation change seems to 
be important for SPI1 expression. However, no molecular 
mechanism behind the change in DNA methylation sta-
tus at SPI1 regulatory regions has been reported yet.
RUNX1 is another TF that is essential for the regula-
tion and maintenance of mammalian hematopoiesis [11]. 
A previous study reported that RUNX1 regulates SPI1 
at both transcriptional and epigenetic levels [9]. RUNX1 
binding at the conserved sites in the URE of SPI1 is criti-
cal for the onset of SPI1 expression during hematopoietic 
stem cell formation, making SPI1 the direct downstream 
target of RUNX1 [12]. At the pre-hematopoietic or 
hemangioblast stage, the inception of RUNX1 expression 
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induces chromatin remodeling at the regulatory regions 
of SPI1, in which the binding of RUNX1 to the SPI1 reg-
ulatory region is essential [9]. Moreover, several studies 
have revealed that chromatin remodeling is coupled with 
DNA demethylation during embryonic development 
[13]. Therefore, we hypothesize that RUNX1 may also 
be involved in recruiting the DNA methylation status 
change at the SPI1 regulatory regions.
Here, we describe that the ectopic expression of 
RUNX1 in HEK-293T cells induces DNA demethylation 
at the two functionally active regulatory regions of SPI1 
in a replication-independent manner.
Results
RUNX1 overexpression induced DNA demethylation at SPI1 
−17‑kb URE
SPI1 contains two regulatory regions; one is the −17-
kb URE that lies upstream of the transcription start site 
(also known as the distal promoter region) and the other 
is the proximal promoter region (Fig. 1). While the −17-
kb URE contains three RUNX1 binding sites (Fig. 2a), the 
proximal promoter region does not contain any such sites 
[14]. To analyze how RUNX1 expression affects the DNA 
methylation status of SPI1 regulatory regions, we first 
focused on the −17-kb URE. We transduced RUNX1-
overexpressing lentivirus into HEK-293T cells, a cell line 
that does not express RUNX1, followed by DNA methyla-
tion analysis by bisulfite sequencing. We observed drastic 
DNA demethylation in RUNX1-overexpressing HEK-
293T cells (Fig.  2b). This DNA demethylation appeared 
to be RUNX1-specific because we did not see any of 
these changes in either MCS-transduced (multiple clon-
ing sites: MCS) or wild-type HEK-293T cells. The region 
as a whole was significantly demethylated (p  <  0.001) 
(Fig. 2c). The DNA demethylation of all individual CpG 
sites investigated at the −17-kb URE was also found to be 
significant (p < 0.005) (Fig. 2d).
RUNX1 overexpression induced partial DNA demethylation 
at SPI1 proximal promoter
The proximal promoter region of SPI1 does not contain 
any binding site for RUNX1 [14] (Fig. 3a); therefore, we 
wondered whether RUNX1 can still induce any change 
in DNA methylation in this region. Our results showed 
that RUNX1 can induce partial demethylation in the 
proximal promoter region, with about 30% of CpGs being 
demethylated (Fig. 3b). Although the demethylation was 
incomplete, the region as a whole was significantly dem-
ethylated (p < 0.0001; Fig. 3c) and the change at most of 
the CpG sites was also found to be significant (p < 0.005; 
Fig. 3d), in comparison to that of MCS-transduced cells.
Molecular mechanism of RUNX1‑induced DNA 
demethylation at SPI1 regulatory regions
DNA demethylation can be active or passive in nature, 
where active demethylation occurs by the enzymatic 
activity of TET enzymes in the absence of replication, 
while passive demethylation occurs slowly during sev-
eral rounds of replication [15]. To identify the type of 
RUNX1-induced demethylation at both SPI1 regulatory 
regions, we used mitomycin-C to arrest cell growth at 
the  G1 phase. Different concentrations of mitomycin-
C were individually tested to identify the concentra-
tion when the ratio of Edu positive cells was zero (no 
DNA synthesis, see “Methods”) (Fig.  4a). We observed 
drastic DNA demethylation in RUNX1-transduced 
cells at the SPI1 −17-kb URE region, even upon mito-
mycin-C treatment, which would prevent passive DNA 
Fig. 1 Schematic representation of SPI1 gene structure: Simplified scheme of the human SPI1 locus, indicating the two regulatory regions of SPI1: 
distal promoter (−17‑kb URE) and proximal promoter. Binding sites for RUNX1 and SPI1 are shown by red and orange boxes, respectively. The red 
horizontal arrows in the URE and the proximal promoter indicate primers designed for methylation study
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demethylation (Fig. 4b). The statistical analysis revealed 
that the region as a whole was significantly demethyl-
ated (p < 0.0001) (Fig. 4c). Significant DNA demethyla-
tion was found at each CpG site investigated (Fig.  4d), 
the same as in the RUNX1-overexpressing cells not 
treated with mitomycin-C, as shown in Fig.  2d. Inter-
estingly, we also observed RUNX1-induced active DNA 
demethylation at the proximal promoter region in mito-
mycin-C-treated cells (Fig.  4e–g). These results dem-
onstrate the ability of RUNX1 to induce active DNA 
demethylation at both SPI1 regulatory regions. Recent 
studies in zebrafish have highlighted that RUNX1 
induces the expression of dnmt3bb.1, a DNMT3 par-
alog in this animal model [16]. Therefore, we next exam-
ined whether RUNX1 overexpression enhanced the 
expression of genes encoding enzymes that are known 
to be involved in both DNA methylation and demeth-
ylation. Specifically, we compared the expression lev-
els of DNMT1, DNMT3A and 3B, TET1-3, and IDH1 
and IDH2 between MCS and RUNX1-transduced cells. 
However, no difference in the expression of these genes 
was observed (Fig. 4h).
RUNX1 induces significant SPI1 expression, but much less 
than in monocytes
DNA methylation at gene regulatory regions generally 
suppresses gene expression, possibly by blocking tran-
scription factor binding at those regions. To examine 
whether RUNX1-induced DNA demethylation at SPI1 
regulatory regions can affect SPI1 endogenous expres-
sion, we measured SPI1 expression in RUNX1-overex-
pressing HEK-293T cells by qRT-PCR. SPI1 endogenous 
expression was significantly (p  <  0.005) induced by the 
RUNX1 ectopic expression, which was estimated to 
involve a 12-fold upregulation, from the differences in 
ΔCt values (Fig. 5). However, the SPI1 expression level for 
RUNX1-overexpressing HEK-293T cells was still far less 
than that of monocytes; only 3% of SPI1 mRNA expres-
sion was estimated.
Discussion
In this study, we found that the ectopic expression 
of RUNX1 in wild-type HEK-293T cells converts the 
methylation status of both SPI1 regulatory regions from 





Fig. 2 DNA methylation status analysis of SPI1 −17‑kb URE in RUNX1‑overexpressing HEK‑293T cells: a Target sequence of human SPI1 −17‑kb URE. 
The number represents the CpG sites and RUNX1 and SPI1 binding sites are shown in bold letters. b Methylation pattern diagrams of wild‑type, MCS, 
and RUNX1‑overexpressing HEK‑293T cells at the SPI1 −17‑kb URE region. Each row of circles represents the result of a single amplicon and each 
column represents those of a single CpG site. Black circles denote methylated CpGs and open circles represent unmethylated ones. The CpG numbers 
shown correspond to the target nucleotide sequence, shown in a. c Quantification of percent CpG methylation at the −17‑kb URE in wild‑type, 
MCS, and RUNX1‑overexpressing HEK‑293T cells. The p‑value calculated from the comparison between MCS and RUNX1‑overexpressing HEK‑293T 
cells was significant (***p < 0.001). d Comparison of methylation status graph at each individual CpG site between MCS and RUNX1‑overexpressing 
HEK‑293T cells. All of the CpGs were significantly demethylated (p < 0.005)
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showed that the induced demethylation was replica-
tion-independent active DNA demethylation. Further, 
RUNX1 overexpression did not change gene expression 
of enzymes involved in both DNA methylation and dem-
ethylation. It has been reported that chromatin remode-
ling of the SPI1 URE region in hemangioblasts is induced 
by the binding of RUNX1, which also accompanies the 
DNA demethylation of this region [9]. This suggests that 
RUNX1 binding directly recruits the DNA demethylating 
machinery. Actually, several TFs have recently shown to 
be involved in DNA demethylation by recruiting DNA 
demethylation machinery [17]. On the other hand, the 
proximal promoter region revealed partial but signifi-
cant DNA demethylation, although it does not contain 
any binding sites for RUNX1 and neither any mechanism 
of its binding is known [12, 14]. Thus, it was interest-
ing to ponder how this replication-independent active 
DNA demethylation occurs at the proximal promoter 
region of SPI1 by the overexpression of RUNX1. Previous 
chromatin immunoprecipitation (ChIP) data have shed 
light on the binding of various transcription factors in 
the URE and proximal promoter regions [8]. Therefore, 
we speculate that other RUNX1-regulated transcrip-
tion factor(s) may also be able to induce DNA demeth-
ylation at both regulatory regions. Thus, we can conclude 
that RUNX1 could be directly or indirectly responsible 
for inducing DNA demethylation at the SPI1 regula-
tory regions, although the actual process remains to be 
confirmed.
Our study also showed that RUNX1 overexpression is 
not sufficient for inducing the higher level of endogenous 
SPI1 expression in HEK-293T cells. The partial demethyl-
ation at the proximal promoter region may be responsible 
for the low level of SPI1 expression. In fact, the proximal 
promoter region of SPI1 is completely hypomethylated in 
monocytes, in which SPI1 is expressed at a higher level 
[18, 19]. Previous reports also suggest the positive cor-
relation between DNA demethylation at gene regulatory 
regions and gene expression, revealing that active genes 
are generally hypomethylated while inactive genes are 
generally hypermethylated at their promoter regions [7, 
20]. Furthermore, the cells with high SPI1 expression reg-
ulate this expression by forming an autoregulatory loop 





Fig. 3 DNA methylation status analysis of SPI1 proximal promoter in RUNX1‑overexpressing HEK‑293T cells: a Target sequence of the human 
SPI1 proximal promoter region. The number represents the CpG sites and the SPI1 binding site is also shown. b Methylation pattern diagrams of 
wild‑type, MCS, and RUNX1‑overexpressing HEK‑293T cells at the SPI1 proximal promoter region. Each row of circles represents the result of a single 
amplicon and each column represents a single CpG site. Black circles denote methylated CpGs and open circles represent unmethylated ones. The 
CpG numbers shown correspond to the target nucleotide sequence, shown in a. c Quantification of percent CpG methylation at the proximal pro‑
moter region in wild‑type, MCS, and RUNX1‑overexpressing HEK‑293T cells. The p value calculated from the comparison between MCS and RUNX1‑
overexpressing HEK‑293T cells was significant (***p < 0.0001). d Comparison of methylation status graph at each individual CpG site between MCS 
and RUNX1‑overexpressing HEK‑293T cells. The significantly demethylated CpG sites are marked with asterisks, ***p < 0.005, **p < 0.01, *p < 0.05
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21], which are in close proximity to each other [22]. Thus, 
our data suggest that the autoregulatory loop may not 
form well due to incomplete demethylation at the proxi-
mal promoter. The presence of other transcription factors 
that are expressed in SPI1-expressing hematopoietic cells 
could also be necessary to induce higher endogenous 
expression of SPI1.
We used HEK-293T cells in this study because they are 
from a cell line that does not express RUNX1. The propen-
sity of these cells to undergo transfection, their availabil-
ity, and the possibility of avoiding passage biasness during 
analysis also make them easy to use. Since our results are 
derived from nonhematopoietic cells by using an artifi-
cial overexpression system, it would be preferable for our 
results to be evaluated further using hematopoietic cell lines 
in which RUNX1 and SPI1 are endogenously expressed. 
However, DNA demethylation at SPI1 regulatory regions 
already occurs at the hematopoietic stem cell stage at which 
RUNX1 is expressed. As the next step, it may be necessary 
to perform such evaluation in hematopoietic cell lines under 
specific conditions or with gene manipulation.
Conclusions
To our knowledge, this is the first study evaluating the 
potential role of RUNX1 as a demethylating inducer. Our 








Fig. 4 Active DNA demethylation at SPI1 regulatory regions. a Quantification of the concentration of mitomycin‑C for cell growth arrest at the 
 G1 phase. b–d Quantification of DNA methylation at the −17‑kb URE with 50 µg/ml mitomycin‑C treatment. b The DNA methylation pattern was 
measured at the −17‑kb URE of MCS‑ and RUNX1‑overexpressing HEK‑293T cells. c The percentage of methylation in MCS‑ and RUNX1‑overexpress‑
ing HEK‑293T cells. d The methylation difference at each individual CpG site between MCS‑ and RUNX1‑overexpressing HEK‑293T cells. All of the 
sites were significantly demethylated (***p < 0.0001). e–g Quantification of DNA methylation at the proximal promoter upon 50 µg/ml mitomycin‑
C treatment. e The DNA methylation pattern was measured at the proximal promoter region of MCS‑ and RUNX1‑overexpressing HEK‑293T cells. f 
Percentage of methylation in MCS‑ and RUNX1‑overexpressing HEK‑293T cells. g The methylation difference at each individual CpG site in MCS‑ and 
RUNX1‑overexpressing HEK‑293T cells. All of the sites were significantly demethylated (***p < 0.0001). h mRNA expression level of genes involved 
in DNA methylation and demethylation in MCS‑ and RUNX1‑overexpressing HEK‑293T cells (Expression value quality control processed signals from 
microarray data. Error bar standard deviation of biological triplicates)
Fig. 5 qRT‑PCR analysis of endogenous SPI1 mRNA expression. The 
endogenous SPI1 mRNA level was examined in the indicated cell 
types. Results are presented after normalization to GAPDH, and data 
are shown as the mean ± SEM (n = 3/cell type). A lower ΔCt value 
depicts higher expression. The significance represented by the p 
value was calculated by two‑tailed and unpaired Student’s t tests, 
with the significance levels shown by asterisks (**p < 0.005)
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Methods
Cell culture and RUNX1 over expression
HEK-293T cells, a human embryonic cell line pro-
vided by Riken Cell Bank (RCB), were cultured in High-
Glucose Dulbecco’s Modified Eagle Medium (DMEM, 
Wako, Japan) supplemented with 10% fetal bovine serum 
(Lonza, Basel, Switzerland) and 2 mM penicillin–strepto-
mycin (Sigma-Aldrich, St. Louis, MO, USA) at 37  °C in 
5%  CO2.
RUNX1 overexpression in HEK-293T cells was carried 
out by using the lentivirus transduction method. The len-
tivirus for RUNX1 overexpression and its control MCS 
were prepared in a mixture of packaging constructs, 
pCMV-VSV-G-RSV-Rev and pCAG-HIVgp (provided by 
RIKEN BRC) in accordance with a previously reported 
protocol [19]. HEK-293T cells (1  ×  106  cells per well) 
were seeded in a poly-d-lysine-coated 12-well plate, fol-
lowed by transduction on the second day by adding 8 µg/
ml polybrene and 10 multiplicity of infection (MOI) of 
lentivirus in each well. One day after the transduction, 
the medium was replaced with fresh DMEM medium 
containing 1 µg/ml puromycin (Thermo Fisher Scientific, 
Waltham, MA, USA) for the selection of transduced cells. 
Cells were harvested 7 days after the transduction. Wild-
type HEK-293T cells were also kept as a control.
Bisulfite sequencing
Genomic DNA was isolated from the harvested cells 
using an All Prep DNA/RNA Mini Kit (Qiagen, Hilden, 
Germany), in accordance with the manufacturer’s proto-
col. The DNA quality was assessed by using a Nanodrop 
1000 (Thermo Fisher Scientific, Waltham, MA, USA). 
DNA bisulfite conversion and purification were per-
formed in accordance with the protocol of the EZ DNA 
Methylation Gold Kit (Zymo Research, Irvine, CA, USA). 
For amplification of the −17-kb URE (326  bp) and the 
proximal promoter region (448  bp), previously reported 
PCR primers [10] were used (Table  1). The amplified 
PCR products were checked on a 1.5% agarose gel, puri-
fied using the PCR purification kit (Qiagen, Hilden, Ger-
many), and then cloned using the Target Clone plus kit 
(Toyobo, Osaka, Japan). Plasmid DNA was isolated using 
the QIAprep 96 Turbo miniprep kit (Qiagen, Hilden, Ger-
many) and sequenced in an ABI 3730xl DNA Analyzer. 
The sequence analysis, including the calculation of meth-
ylation percentage, methylation pattern change, and com-
parison at each CpG site, was performed using the online 
software QUMA (http://quma.cdb.riken.jp/).
Cell cycle arrest
HEK-293T cells (2 × 106 cells per well) were plated into 
a six-well plate, treated with different concentrations 
of mitomycin-C (Sigma-Aldrich, St. Louis, MO), and 
incubated for 4 h at 37 °C in 5%  CO2. To check cell cycle 
arrest (at the  G1 phase), the proliferation assay was per-
formed by following the Click-iT® EdU Cytometry Cell 
Proliferation Assay protocol (Thermo Fisher Scientific, 
Waltham, MA, USA); for assessment, FACS was used. 
After the confirmation of cell cycle arrest at 50  µg/ml 
mitomycin-C, the cells were plated and transduced with 
RUNX1 lentivirus on the second day by following the 
above-mentioned protocol. Wild-type 293T cells were 
also treated with 50 µg/ml mitomycin-C and transduced 
with MCS, which were kept as a control.
DNA microarray
Total RNA was isolated by using the  Nucleospin® RNA 
kit protocol (Macherey–Nagel, Germany). Five hundred 
nanograms of total RNA was amplified using the Ambion 
total RNA amplification kit (Ambion, Carlsbad, CA), fol-
lowed by hybridization of the synthesized cRNA with the 
Human HT-12 v4 Expression BeadChip kit (Illumina, San 
Diego, CA, USA), in accordance with the manufacturer’s 
protocol. Scanning of the chip was performed using Illu-
mina BeadScan and BeadStudio (version 3.1). Data were 
processed with a package from Bioconductor (lumi) [23, 
24] using the free software environment R (http://www.r-
project.org/). The microarray data has been registered in 
gene expression omnibus (https://www.ncbi.nlm.nih.gov/
geo/) in NCBI (GSE95308).
qRT‑PCR
Total RNA was isolated using the  Nucleospin® RNA kit 
protocol (Macherey–Nagel, Germany). Reverse tran-
scription of total RNA was performed using the Prime 
Script RT kit (Takara, Takara Bio, Japan); qRT-PCR was 
performed with the ABI  PRISM® 7500  sequence detec-
tion system (Applied Biosystems, USA) using SYBR Pre-
mix Ex Taq™ II (Tli RNaseH plus, Takara Bio, Japan) and 
gene-specific primers for SPI1 and GAPDH (Table  1). 
PCR cycling conditions consisted of initial denaturation 
at 95  °C for 10  s, followed by 40 cycles at 95  °C for 5  s 
and 60  °C for 30  s. Data was analyzed using the  2−ΔΔCt 
Table 1 List of primers used for bisulfite PCR and qRT-PCR
Bisulfite primers
 SPI1 proximal promoter (Fwd) GAGATTTTTTGTATGTAGTGTAAGA
 SPI1 proximal promoter (Rv) TAACTTCCCACTAATAACAAACCA
 SPI1 −17‑kb URE (Fwd) GTTGGATATTTTTTTGAGGTTTGG
 SPI1 −17‑kb URE (Rv) TAAAACCTAAAACTACTAAACCCA
Real‑time primers
 GAPDH (Fwd) GAAATCCCATCACCATCTTCCAGG
 GAPDH (Rv) GAGCCCCAGCCTTCTCCATG
 SPI1 (Fwd) TCCTGAGGGGCTCTGCATT
 SPI1 (Rv) TGTCATAGGGCACCAGGTCTT
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method [25]. Human peripheral blood  CD14+ mono-
cytes (Lonza, Basel, Switzerland) were kept as a positive 
control for the comparison of SPI1 expression.
Statistical analysis
All of the statistical analyses for DNA methylation sta-
tus and calculation of methylation percentage were per-
formed using the online quantification tool QUMA. The 
significance of differences between the transduced and 
untransduced cells was determined by using unpaired, 
two-tailed, and Student’s tests (t test), where p < 0.05 was 
considered significant.
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